Bacillus amyloliquefaciens SCGB1
Bacillus amyloliquefaciens SCGB1 has a small research profile, with two papers in the index reflecting distinct lines of inquiry. A 2021 animal study examined oral administration of SCGB1 in a mouse model of experimental colitis (a chemically induced model of gut inflammation), with proposed mechanisms involving immune regulation. A 2026 in vitro study examined polystyrene-degrading bacteria, including B. amyloliquefaciens, in the context of host stress and toxicity responses to microplastic exposure in Caenorhabditis elegans, a model organism used for toxicology research. Both lines of research are early-stage animal and in vitro work. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 2 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
3 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 41818344 →Polystyrene-degrading bacteria modulate host stress and toxicity responses to microplastic exposure in Caenorhabditis elegans· The ISME Journal · 2026